Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-Market Study of Performance and Safety of Low-flow Extracorporeal Carbon Dioxide Removal Using PrismaLung+ in Patients With Mild to Moderate Acute Respiratory Distress Syndrome

NCT04617093 is registered in ClinicalTrials.gov with Vantive Health LLC as lead sponsor.

NCT NCT04617093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04617093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-Market Study of Performance and Safety of Low-flow Extracorporeal Carbon Dioxide Removal Using PrismaLung+ in Patients With Mild to Moderate Acute Respiratory Distress Syndrome
Lead sponsor
Vantive Health LLC
Phase
Not applicable
Overall status
Completed
Start date
April 30, 2021
Completion date
January 10, 2024
Enrollment
63 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

mild to moderate acute respiratory distress syndrome